Accumulated Other Comprehensive Income (Loss), Net of Tax of Universe Pharmaceuticals INC from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Universe Pharmaceuticals INC quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Universe Pharmaceuticals INC Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending 30 Sep 2025 was $1,813,522.
Source SEC data
View on sec.gov
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Change (%)

Universe Pharmaceuticals INC Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,813,522 +$1,110,332,478 30 Sep 2025 20-F 29 Jan 2026 2025 FY
Q3 2024 $1,112,146,000* -$1,109,773,760 30 Sep 2024 20-F 29 Jan 2026 2025 FY
Q1 2024 $2,100,414 -$1,833,484 -687% 31 Mar 2024 6-K 20 Sep 2024 2024 Q2
Q3 2023 $2,372,240 -$705,535 -42% 30 Sep 2023 20-F 29 Apr 2025 2024 FY
Q1 2023 $266,930 -$2,847,883 -110% 31 Mar 2023 6-K 31 Aug 2023 2023 Q2
Q3 2022 $1,666,705 -$3,755,464 -180% 30 Sep 2022 20-F 30 Jan 2024 2023 FY
Q1 2022 $2,580,953 31 Mar 2022 6-K 16 Aug 2022
Q3 2021 $2,088,759 +$1,193,369 +133% 30 Sep 2021 20-F 10 Feb 2023 2022 FY
Q3 2020 $895,390 30 Sep 2020 20-F 31 Jan 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.